AORT Overview

Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons in treating patients with aortic diseases. The Company operates through two segments, which include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other products. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products. It is engaged in the endovascular repair of aortic arch disease and the developer of the NEXUS Aortic Arch System.

Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is51.71 USD with a low forecast of 40.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Artivion Inc revenue for the last quarter amounts to 116.34M USD, increased 17.54

Artivion Inc. EPS for the last quarter amounts to 0.03 USD, decreased -400.00

Artivion Inc (AORT) has 1800 emplpoyees as of May 31 2026.

Today AORT has the market capitalization of 1.08B USD.